Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Mutation-positive NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05786430
What this trial is testing

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Who this might be right for
Non-small Cell Lung Cancer
Yonsei University 87
Testing effectiveness (Phase 2)Active Not RecruitingNCT05526755
What this trial is testing

5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Who this might be right for
Stage II-IIIB Non-small Cell Lung Carcinoma
AstraZeneca 188
Testing effectiveness (Phase 2)UnknownNCT03420079
What this trial is testing

A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation

Who this might be right for
Lung Cancer
Ahon Pharmaceutical Co., Ltd. 90
Not applicableStudy completedNCT03370770
What this trial is testing

Afatinib Osimertinib Sequencing NIS

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 204
Not applicableUnknownNCT06352502
What this trial is testing

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

Who this might be right for
EGF-R Positive Non-Small Cell Lung CancerCNS Metastases
Tang-Du Hospital 30
Large-scale testing (Phase 3)Active Not RecruitingNCT05120349
What this trial is testing

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 390
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Not applicableStudy completedNCT02777658
What this trial is testing

PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 169
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Not applicableStudy completedNCT01947868
What this trial is testing

Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor

Who this might be right for
Non-Small-Cell Lung Cancer
AstraZeneca 346
Not applicableLooking for participantsNCT05033691
What this trial is testing

Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

Who this might be right for
NSCLCEGFR Gene MutationEGF-R Positive Non-Small Cell Lung Cancer+2 more
Hadassah Medical Organization 162
Early research (Phase 1)Study completedNCT02914990
What this trial is testing

Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 36
Testing effectiveness (Phase 2)UnknownNCT03126799
What this trial is testing

Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
National Cancer Center, Korea 128
Not applicableActive Not RecruitingNCT03969823
What this trial is testing

Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Seoul National University Hospital 148
Early research (Phase 1)Study completedNCT02163733
What this trial is testing

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 38
Not applicableStudy completedNCT03219970
What this trial is testing

Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 156
Testing effectiveness (Phase 2)Study completedNCT01941654
What this trial is testing

ATOM_local Ablative Therapy

Who this might be right for
NSCLCActivating EGFR Mutation
Chinese University of Hong Kong 18
Large-scale testing (Phase 3)Active Not RecruitingNCT03787992
What this trial is testing

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 358
Not applicableStudy completedNCT03133234
What this trial is testing

Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

Who this might be right for
T790M Positive NSCLC Patients
AstraZeneca 47
Testing effectiveness (Phase 2)Study completedNCT03455829
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungLung CancerNon-small Cell Lung Cancer
G1 Therapeutics, Inc. 30
Next Page